Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Lymphocytes upregulate CD36 in adipose tissue and liver

Couturier J., Nuotio-Antar AM., Agarwal N., Wilkerson GK., Saha P., Kulkarni V.

Animal Study, published in Adipocyte (2019) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Adipocyte (2019)
Reported sample size
—
Source database
Europe PMC
PMID
31035848
PMCID
PMC6768236
DOI
10.1080/21623945.2019.1609202
Citations
19

Abstract (original English)

CD36 is a multifunctional scavenger receptor and lipid transporter implicated in metabolic and inflammatory pathologies, as well as cancer progression. CD36 is known to be expressed by adipocytes and monocytes/macrophages, but its expression by T cells is not clearly established. We found that CD4 and CD8 T cells in adipose tissue and liver of humans, monkeys, and mice upregulated CD36 expression (ranging from ~5-40% CD36+), whereas little to no CD36 was expressed by T cells in blood, spleen, and lymph nodes. CD36 was expressed predominantly by resting CD38-, HLA.DR-, and PD-1- adipose tissue T cells in monkeys, and increased during high-fat feeding in mice. Adipose tissue and liver promote a distinct phenotype in resident T cells characterized by CD36 upregulation.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
LiverAdipose TissueCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesAnimalsMice, Inbred C57BLMacaca mulattaHumansMiceUp-Regulation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.